Akèy › Kansè nan tete › Nevada › Reno
Etid klinik pou Kansè nan tete nan Reno, NV
13 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Reno (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Cancer Care Specialists, Reno
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Renown Regional Medical Center, Reno
- Saint Mary's Regional Medical Center, Reno
- Carson Tahoe Regional Medical Center, Carson City · 25 mi lwen
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Ap rekriteFaz 2
- Cancer Care Specialists, Reno
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- Renown Regional Medical Center ( Site 0041), Reno
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Ap rekriteFaz 1/2
- Renown Regional Medical Center, Reno
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Ap rekriteFaz 3
- Research Site, Reno
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- Renown Health Medical Oncology, Reno
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Ap rekriteEtid obsèvasyon
- Cancer Care Specialist of Reno, Reno
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Renown Regional Medical Center, Reno
- Saint Mary's Regional Medical Center, Reno
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi lwen
- ak 1 plis
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi lwen
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Ap rekriteFaz 3
- Renown Regional Medical Centre, Reno
- Cancer Care Specialists, Reno
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Renown Regional Medical Center, Reno
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi lwen
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Ap rekriteFaz 1
- Renown Regional Medical Center, Reno
Etid Kansè nan tete nan lòt vil
- New York City, NY134 etid
- Houston, TX126 etid
- Boston, MA111 etid
- Nashville, TN80 etid
- Los Angeles, CA72 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Durham, NC63 etid
- Queens, NY63 etid
- Chicago, IL58 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Reno
- Kansè Poumon ki pa ti selil16 etid
- Kansè poumon9 etid
- Degeneresans makile8 etid
- Atrofi Jeyografik8 etid
- Kansè ovè7 etid
- Kansè (tout kalite)7 etid
- Kansè kolorektal5 etid
- Leksemi mieloïd egi5 etid
- Kansè Metastatik5 etid
- Kansè pankreyas5 etid
- Kansè kolon5 etid
- Kansè rektal4 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.